Expert Opinion on Pharmacotherapy

Expert Opinion on Pharmacotherapy is a subscription-based, MEDLINE-indexed review journal published by Taylor and Francis, established in 1999, that offers expert opinion on new pharmaceutical agents and their impact on treatment, with a 2025 impact factor of 3.4（Expert Opinion on Pharmacotherapy）是由（Taylor & Francis）出版的订阅制综述期刊，被 MEDLINE 收录，1999 年创办，针对新药及其对治疗的影响提供专家意见，2025 年影响因子为 3.4。

Scope

• Review articles on new drugs and drug classes from late-stage development to recently marketed agents评述新药与药物类别（从开发后期到刚上市）的综述文章。
• Drug evaluations reviewing the clinical and pharmacological data on a particular drug针对某一药物临床与药理学数据展开的药物评价。
• Original research on agents in phase III and IV trials with a strong link to clinical practice针对 III、IV 期试验药物、且与临床实践紧密相关的原创研究。
• Articles that incorporate the author's own expert opinion on future development融入作者本人对未来发展方向之专家意见的文章。
• The journal does not publish case reports, case series or animal studies该刊不发表病例报告、病例系列或动物研究。

History

• The journal was established in 1999 under Informa Pharma Science, formerly Ashley Publications该刊于 1999 年由（Informa Pharma Science）（前身为 Ashley Publications）创办。
• It belongs to the Expert Opinion and Expert Collection brands now published by Taylor and Francis该刊属于现今由（Taylor & Francis）出版的专家意见／专家合集系列。
• It appears eighteen times a year该刊每年发行十八期。
• It reports a 2025 impact factor of 3.4 and an acceptance rate of about 29 percent该刊 2025 年影响因子为 3.4，录用率约为 29%。

Editors

• The editor-in-chief is Gary Tse of Hong Kong Metropolitan University现任主编为（Hong Kong Metropolitan University）的 Gary Tse。
• A large international editorial advisory board supports the journal, drawn from the United States, Italy, Poland, Germany, Greece, Canada, the United Kingdom and Hong Kong, among others一个庞大的国际编辑顾问委员会为该刊提供支持，成员来自美国、意大利、波兰、德国、希腊、加拿大、英国与中国香港等地。
• Manuscripts are first assessed by the editorial team and then double-anonymous peer reviewed稿件先经编辑团队评估，随后进行双匿名同行评审。
• Pre-submission enquiries are handled through the commissioning editor投稿前咨询由组稿编辑（Commissioning Editor）负责。